AstraZeneca shares rise as fresh reports deny mega-merger talks with US rival

Astra's stock climbed 2.5% or 296p to 12,036p after Reuters quoted a senior source at the business quashing rumours of any potential tie-up.

Shareholders question looming patent cliff and antitrust risks in potential $400bn tie-up with Bristol Myers Squibb

Astrazeneca’s share price declined sharply in early trading after investors cast doubt over the potential merger with its US rival. The UK drugmaker’s shares suffered a six per cent decline in early trading to 11,866p, after reports it was exploring a possible $400bn megadeal with Bristol Myers Squibb.  The FTSE 100 gi

The merger would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company

The move would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company.

The move would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company.